

CITATION REPORT

List of articles citing

SGLT1 inhibition boon or bane for diabetes-associated cardio

DOI: 10.1111/fcp.12516

Fundamental and Clinical Pharmacology, 2020, 34, 173-188.

Source: <https://exaly.com/paper-pdf/75111272/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534, a potent G protein-coupled receptor 40 (GPR40) agonist, at single- and multiple-ascending oral doses in healthy Chinese subjects. <i>Xenobiotica</i> , 2021 , 51, 297-306	2	0
5	Plasma gonadotropin levels in metformin-treated men with prediabetes: a non-randomized, uncontrolled pilot study. <i>Fundamental and Clinical Pharmacology</i> , 2021 , 35, 466-472	3.1	5
4	Meet Our Editorial Board Member. <i>Current Pharmaceutical Biotechnology</i> , 2021 , 22, 1013-1013	2.6	
3	A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure. <i>Cardiology Research</i> , 2021 , 12, 60-66	1.8	6
2	Canagliflozin and Dapagliflozin Attenuate Glucolipotoxicity-Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Inhibition of Sodium-Glucose Cotransporter-1.. <i>ACS Pharmacology and Translational Science</i> , 2022 , 5, 216-225	5.9	1
1	Sodium-glucose co-transporter 2 inhibitors: A comprehensive review from cells to bedside.		0